BC-6213 (B&C-Pharma)

N/A

Report date: 2024/12/04 11:15:59

NME

Base Information

Drug NameBC-6213 (B&C-Pharma)

Drug Alias NameBC-6213

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionRunt-related transcription factor 2 modulators

TargetsRunt-related transcription factor 2

Therapy Area/IndicationsOsteoporosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesB&C Pharma

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesB&C Pharma

Active IndicationsN/A

Inactive IndicationsOsteoporosis

ATC CodeN/A